Biotech industry relies heavily on IPOs

Initial public offerings (IPO) and secondary offerings provide early-stage biotech companies with the financial support required to advance drugs through clinical development. Since the Global Financial Crisis, biotech companies have fallen significantly from their high participation in the IPO market. As a result, at the start of 2010, public biotech companies had reached later stages of drug development cycles compared to biotech companies raising public capital today.